Djordje Pavlovic

University of Rijeka

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Miguel Romero

Hospital Universitario Reina Sofía

Manuel Pan

Hospital Universitario Reina Sofía

José Suárez de Lezo

Hospital Universitario Reina Sofía

José Segura

Universidad Complutense de Madrid

Soledad Ojeda

Instituto Maimónides de Investigación Biomédica de Córdoba

Alfonso Medina

Epsom and St Helier University Hospitals NHS Trust

Enrique Hernández

Albert Einstein College of Medicine

Francisco Melián

Hospital Universitario de Gran Canaria Doctor Negrín

Francisco Mazuelos

Hospital Universitario Reina Sofía

António Delgado

Friedrich-Alexander-Universität Erlangen-Nürnberg

Cooperative Institutions

University of Turku

257

Universitat de Barcelona

203

TU Dortmund University

199

Centre National de la Recherche Scientifique

196

Institut d'Estudis Espacials de Catalunya

188

Max Planck Institute for Physics

187

University of Łódź

183

Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas

139

Niels Brock

124

University of Copenhagen

122

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Can Pharmacogenetic Variants in TPMT, MTHFR and SLCO1B1 Genes Be Used as Potential Markers of Outcome Prediction in Systemic Sclerosis Patients?

International Journal of Molecular Sciences (2023)

Marina Jelovac Nikola Kotur Bojan Ristivojević Djordje Pavlovic Vesna Spasovski

Systemic sclerosis (SSc) is a rare connective tissue disorder with highest morbidity and mortality among rheumatologic diseases. Disease progression is highly heterogeneous between patients, implying a strong need for individualization of therapy. Four pharmacogenetic variants, namely TPMT rs1800460, TPMT rs1142345, MTHFR rs1801133 and SLCO1B1 rs4149056 were tested for association with severe disease outcomes in 102 patients with SSc from Serbia treated either with immunosuppressants azathioprine (AZA) and methotrexate (MTX) or with other types of medications. Genotyping was performed using PCR-RFLP and direct Sanger sequencing. R software was used for statistical analysis and development of polygenic risk score (PRS) model. Association was found between MTHFR rs1801133 and higher risk for elevated systolic pressure in all patients except those prescribed with MTX, and higher risk for kidney insufficiency in patients prescribed with other types of drugs. In patients treated with MTX, variant SLCO1B1 rs4149056 was protective against kidney insufficiency. For patients receiving MTX a trend was shown for having a higher PRS rank and elevated systolic pressure. Our results open a door wide for more extensive research on pharmacogenomics markers in patients with SSc. Altogether, pharmacogenomics markers could predict the outcome of patients with SSc and help in prevention of adverse drug reactions.

SLCO1B1

Pharmacogenomics

Thiopurine methyltransferase

10.3390/ijms24108538

Cite

Citations (3)

Balloon valvuloplasty for mild mitral stenosis

Catheterization and Cardiovascular Diagnosis (1991)

Manuel Pan Alfonso Medina José Suárez de Lezo Miguel Romero Enrique Hernández

Abstract Of a total number of 288 patients with mitral stenosis treated by percutaneous balloon valvuloplasty, 21 patients had a basal mitral area equal to or greater than 1.5 cm 2 , as measured hemodynamically. The immediate hemodynamic results of this particular group of patients with mild mitral stenosis are described, as well as the clinical and echo doppler findings at follow‐up (22 ± 12 mo). Patients with mild mitral stenosis (group I) had more pliable valves (p < 0.01), as assessed by echo, and higher incidence of sinus rhythm (p < 0.02) than that observed in the remaining 267 patients (group II). After valvuloplasty the valve area increased in group I from 1.7 ± 0.2 to 3.1 ± 0.7 cm 2 (p < 0.0001). This mean final area was significantly different (p < 0.0001) than that observed in group II (1.98 ± 0.6 cm2). No patients with mild mitral stenosis developed progression of mitral regurgitation, and none had any other major complications. Most of them reached a grade I final functional status. At echo doppler follow‐up studies we did not observe significant changes in the mean mitral gradient as compared with the immediate hemodynamic results. These findings suggest that early mitral balloon valvuloplasty could be an alternative in trying to favorably Influence the natural course of the rheumatic mitral disease in selected patients.

Mitral valve stenosis

Mitral valvuloplasty

10.1002/ccd.1810240102

Cite

Citations (22)

[Directional coronary atherectomy in ostial lesions of the anterior descending coronary artery].

PubMed (1996)

A Gallárdo Pán M Sánchez Medina Miguel Romero Francisco Melián

Ostium

Atherectomy

Balloon dilation

Source

Cite

Citations (0)

Resultados a largo plazo del tratamiento mediante dilatación con balón en pacientes con estenosis subaórtica de membrana: un estudio de 24 años

Cardiocore (2011)

Daniel García‐Fuertes José Suárez de Lezo‐Cruz Conde José María Segura-Saint Gerons Manuel Pan Miguel Romero

10.1016/j.carcor.2011.03.005

Cite

Citations (0)

Abstract 14838: Bone Marrow Stem-Cell Therapy for Idiopathic Dilated Cardiomyopathy

Circulation (2011)

José Suárez de Lezo Miguel Romero Inmaculada Herrera Manuel Pan María Dolores Carmona-Luque

Bone marrow stem-cell therapy (BMSCT) has been used for functional recovery in patients (pts) with acute and chronic ischaemic heart disease. However, less information is available in pts with non-...

Dilated Cardiomyopathy

Stem Cell Therapy

Source

Cite

Citations (0)

DEEP MULTI-INSTANCE LEARNING FOR CLASSIFYING CANCER TYPES IN ENDOMETRIAL BIOPSIES

Journal of Pathology Informatics (2022)

Sasa Andjelkovic Sinisa Todorovic Djordje Pavlovic Stacy L. Littlechild Igor Mihajlovic

10.1016/j.jpi.2022.100076

Cite

Citations (0)

Abstract 3249: Clinical Outcome of Patients with Coronary Restenosis After Drug Eluting Stents

Circulation (2006)

José Suárez de Lezo José Segura Manuel Pan Alfonso Medina António Delgado

Coronary stenting

Source

Cite

Citations (0)

Combined coronary artery revascularization and percutaneous aortic valve implantation in elderly patients

European Heart Journal (2013)

Francisco Mazuelos José Segura José Suárez de Lezo Djordje Pavlovic Pedro Martín

The combination of coronary atery revascularization and transcatheter aortic valve implantation might increase the risk and have some influence in the outcome of elderly patients. We analyzed the influence of combined coronary artery revascularization on the outcome of patients with degenerative aortic stenosis treated by transcatheter aortic valve implantation (TAVI). Methods: Between April 2008 and December 2012, 191 patients with aortic stenosis were treated by TAVI (CoreValve); 139 (73%) had no significant coronary disease (group I), and 52 (27%) presented coronary artery disease that was treated percutaneously before TAVI implantation (group II). Patients were followed-up for a mean of 23±17 months. We defined major events as death, stroke, myocardial infarction or readmission for congestive heart failure (CHF). Results: The mean age at treatment was 78±5 years. Admission for rest angina was more frequent in patients from group II (22% vs 6%; p<0.05). There were no significant differences in baseline characteristics from group I and II, in terms of age, logistic EuroScore and incidence of diabetes, hypertension, smokers, atrial fibrillation, chronic pulmonary disease or chronic renal failure. Hemodynamic and angiographic baseline data were also similar in both groups (aortic valve area, left ventricular ejection fraction). In group II, 34 patients (66%) had single vessel disease and 18 (34%) multi-vessel disease. All these patients underwent stent implantation 2±1 months prior to TAVI. Drug-eluting stents were implanted in 23 (44%) patients, while 29 (56%) received bare metal stents. Both groups of patients received similar TAVI treatment, with no differences in terms of valve size, need for post-dilation or permanent pacemaker implantation. Procedural success was achieved in 137 patients (91%) in group I and in 47 patients (90%) in group II (p: ns), 12 patients (8.6%) died in hospital in group I and 2 patients (4%) in group II (p: ns). During follow-up, 10 patients (8%) presented late death in group I vs 9 (17%) in group II (p: ns). The incidence of stroke was 5 (3%) –group I- vs. 6 (11%) –group II- (p: ns). The readmission rate due to CHF was 8 (6%) –group I- vs 3 (6%) –group II- (p: ns). There were no myocardial infarction in both groups. The Kaplan Meier event free probability for major events at 3 years was 76% –group I- vs. 70% –group II- (p: ns). Conclusions: Co-existing coronary artery disease treated with percutaneous stenting does not seem to influence the outcome negatively in patients with degenerative aortic stenosis treated by TAVI.

EuroSCORE

10.1093/eurheartj/eht310.p5415

Cite

Citations (0)

Simple and complex stent strategies for bifurcated coronary arterial stenosis involving the side branch origin

The American Journal of Cardiology (1999)

Manuel Pan José Suárez de Lezo Alfonso Medina Miguel Romero Enrique Hernández

Ostium

Circumflex

10.1016/s0002-9149(99)00093-4

Cite

Citations (123)